Cargando…
Efficacy and Safety of Lasmiditan as a Novel Acute Treatment in Chinese Patients with Migraine: A Subpopulation Analysis of the Randomized Controlled Phase 3 CENTURION Trial
INTRODUCTION: Over the last two decades, there has been no novel acute treatment for migraine to address the large unmet medical need in Chinese patients. Lasmiditan, a novel selective serotonin 1F receptor agonist (ditan), is anticipated to bring clinical benefit in Chinese patients with migraine....
Autores principales: | Yu, Tingmin, He, Li, Yang, Xiaosu, Zhou, Jiying, Luo, Guogang, Wang, Hebo, Zhao, Hongru, Hu, Quan, Ji, Fei, Yu, Shengyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338201/ https://www.ncbi.nlm.nih.gov/pubmed/35713760 http://dx.doi.org/10.1007/s40120-022-00369-1 |
Ejemplares similares
-
Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine
por: Tassorelli, C, et al.
Publicado: (2021) -
Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study
por: Ashina, Messoud, et al.
Publicado: (2021) -
The potential of lasmiditan in migraine
por: Mecklenburg, Jasper, et al.
Publicado: (2020) -
The new centurions /
por: Wambaugh, Joseph
Publicado: (1972) -
Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)